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occurs in patients experiencing the consequences of what
was likely a single infectious bite by an anopheline mosqui-
to. A single species of parasite is nearly always involved and
expert opinion on malaria chemotherapy uniformly pre-
scribes species- and stage-specific treatments. However the
vast majority of people experiencing malaria, those resident
in endemic zones, do so repeatedly and very often with the
involvement of two or more species and stages of parasite.
Silent forms of these infections—asymptomatic and beyond
the reach of diagnostics—may accumulate to form substan-
tial and unchallenged reservoirs of infection. In such set-
tings treating only the species and stage of malaria revealed
by diagnosis and not others may not be sensible or appro-
priate. Developing therapeutic strategies that address all
species and stages independently of diagnostic evidence
may substantially improve the effectiveness of the control
and elimination of endemic malaria.
Keywords Malaria . Relapse . Primaquine . G6PD
deficiency . Radical cure . Gametocytocidal
Introduction
Infection of humans by sporozoan parasites of the genus
Plasmodium causes malaria. That term describes a diverse
passing through complex life cycles of morphologically and
physiologically distinctive forms, each of which manifests
clinical consequences ranging from none to death. Protean
life threatening syndromes occur among the species at rates
ranging from often to very rare: coma, severe anemia, res-
piratory distress, renal or hepatic failure, shock, splenic
infarct or rupture, and splenomegaly. Specific forms of para-
sites appear only within a particular host (human or mos-
quito) and organ (human liver or blood), and each exhibits
unique susceptibilities to various chemotherapeutic agents
[1]. A drug that kills one stage typically has little effect on
other stages. Some drugs may kill a particular stage of one
species but not the same stage of another (Table 2). Species-
and stage-specific resistance to drugs varying geographi-
cally greatly deepens the complexity of the chemotherapeu-
tic problem. Rational strategy for the chemotherapeutic
management of patients with malaria thus requires expert
biological, pharmacological, epidemiological, and clinical
considerations.
Malaria treatment guidelines from authoritative agencies
invariably list recommendations according to species of
parasite and stage targeted [2, 3]. Malariologists and health-
care providers alike maintain this segregation, as do devel-
opers of those chemotherapies. Species- and stage-specific
treatment guided by a confirmed diagnosis is the keystone
of malaria chemotherapeutics strategy and practice. There is
obvious appeal in this approach, i.e., mitigating the daunting
complexity of the malaria chemotherapeutics problem to
manageability in practice [4]. This may be especially prac-
tical in non-endemic zones where malaria patients typically
have access to state-of-the-art diagnostics and present with a
single species diagnosis. In contrast, patients in endemic
zones often carry two or more species and stages of parasite
out of diagnostic reach for technical or practical reasons.
Directing therapy only against that which diagnosis affirms
may not be sensible—it may virtually ensure incomplete
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Abstract Most malaria diagnosed outside endemic zones set of diseases provoked by at least five species (Table 1)
and ineffective chemotherapeutics in the context of control
or elimination of the endemic malarias. Should malaria
treatment in endemic zones be separated, in both a strategic
and material sense, from that for patients elsewhere? This
review examines evidence on this important question.
Northern Chemotherapeutics Bias
Resource-rich and endemic malaria-free nations of the
Northern hemisphere set the malaria chemotherapy agenda
during the 20th Century and continue doing so [5]. Chemo-
therapeutics strategies and resources have focused almost
exclusively on the acute attack of falciparum malaria. This
carries important ramifications for endemic nations, i.e., ne-
glect of chemotherapeutic attack of the many other malarias.
The blurring of chemotherapeutics strategies aimed at travel-
ers versus residents sharply inhibits development of therapies
relevant to malaria control and elimination. Treatment as a key
element of a larger malaria control strategy that includes
rational attack on all of the endemic malarias has been grossly
neglected [6].
Many drugs are available for one stage and species—the
disease-causing asexual blood stages of Plasmodium falci-
parum. This has long been, and continues to be, the chemo-
therapeutic imperative of antimalarial drug developers.
These therapies may also be applied to cure acute attacks
of other species, but recommendations for such rarely come
Table 1 The malarias of humans
P. falciparum P. vivax P. malariae P. ovale P. knowlesi
Epidemiology Endemic/Epidemic;
pan-tropical exclud-
ing South Pacific
east of Braxton Line
Endemic/Epidemic; pan
tropical excluding South
Pacific east of Braxton
Line, and sub-tropical and
temperate
Endemic but highly
focal; pan-tropical
excluding South Pa-
cific east of Braxton
Line
Endemic in Africa;
endemic at very low
frequencies in South
Asia, Southeast Asia,
and Oceania west of
Braxton Line
Zoonosis from
macaques native
to Southeast
Asia; forested
areas only
Consequence Very often life-
threatening
Often life-threatening Rarely life-threatening Rarely life-threatening Often life-
threatening
Threatening
syndromes
Anemia, cerebral,
hyper-parasitemia,
pulmonary, renal,
hepatic, shock
Anemia, cerebral,
pulmonary, renal, hepatic,
hemorrhage, shock,
splenic rupture
Renal, splenomegaly Pulmonary, shock Cerebral,
pulmonary,
renal, hepatic,
shock
Chronic sub-
patency or laten-
cy forms
Asexual & sexual
blood stages in the
semi-immune
Asexual & sexual blood
stages in the semi-immune;
dormant stage in liver up
to 3 years
Asexual & sexual
blood stages in any
patient, very long
term latency of
several decades
Asexual and sexual
blood stages in the
semi-immune; dor-
mant stage in liver
None known
Diagnostic blind
spots
Parasitemia <200/μL
(RDT); <20/μL
(expert microscopy);
<1/μL (PCR)
Parasitemia <500/μL (RDT);
<20/μL (expert
microscopy); <1/μL
(PCR); dormant liver
stage; bone marrow (?)
Parasitemia <200/μL
(RDT); <20/μL
(expert microscopy);
<1/μL (PCR)
Parasitemia <500/μL
(RDT); <20/μL (expert
microscopy); <1/μL
(PCR); dormant liver
stages
No RDT; \<20/μL
(expert
microscopy);
<1/μL (PCR)
Radical cure Blood schizontocide(s)
+ gametocytocide
Blood schizontocide(s) +
hypnozoitocide
(gametocytocide)
Blood schizontocide(s)
+ gametocytocide
Blood schizontocide +
hypnozoitocide
(gametocytocide)
Blood
schizontocide +
gametocytocide
Table 2 Mosaic of the effects of some antimalarials at therapeutic doses against stages of P. falciparum and P. vivax malarias
AF antifolates; AR artemisinins; CQ chloroquine; MQ mefloquine; PQ primaquine; QN quinine; TQ Tafenoquine
Red 0 effective; Pink 0 effective but with resistance in some strains; Yellow 0 limited effect; Black 0 no effect; Blue 0 effective but only in
combination with primaquine (the only drugs now known to synergize primaquine and tafenoquine activity against hypnozoites)
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with adequate evidence of safety and efficacy, much less
optimized dosing. The non-falciparum acute malarias have
long been viewed as far less threatening to life and thus
relatively unimportant [7, 8]. The zoonosis of Plasmodium
knowlesi is certainly threatening, but relatively infrequent.
The view of vivax malaria as a benign infection has been
recently challenged with evidence of substantial burdens of
morbidity and mortality in endemic zones [9–12, 13••]. The
misperception of Plasmodium vivax as a benign entity large-
ly explains the neglect of therapies aimed at its dormant
liver stage, the hypnozoites causing relapses—P. falciparum
does not form hypnozoites and has no known chronic latent
stage. Gametocytes of any species pose no direct clinical
threat to patients and their treatment has been likewise
neglected.
The only drug with a licensed indication for therapy
aimed at hypnozoites or gametocytes is primaquine. That
drug causes mild to severe hemolysis in patients having
glucose-6-phosphate dehydrogenase deficiency (G6PDd),
an inborn and typically silent disorder most common in
malaria endemic zones [14]. The exclusion of such patients
from risky primaquine treatments rarely occurs in endemic
zones for lack of laboratory capacities where most malaria
patients live. These providers rarely prescribe a potentially
threatening therapy against an infection perceived (inappro-
priately) as non-threatening. Regimens of primaquine thera-
py demonstrated to be safe among the most sensitive variants
of G6PDd, and thus useful without the necessity of screening,
have not been adequately explored. Consequently, despite this
drug being potentially extremely useful in controlling malaria,
it remains rarely used in endemic zones and thus largely
ineffective in a global malaria sense [15•].
Primaquine in the hands of providers able to routinely
and safely exclude G6PDd patients is very often prescribed
(>87% [16]). Primaquine was developed and optimized for
use by the US military, and it has effectively served that and
similar populations for over five decades. Its impracticality
and ineffectiveness in endemic zones largely escaped notice
and solutions to the problem, e.g., universally safe dosing or
a simple point-of-care G6PDd diagnostic device, have not
emerged. The chemotherapeutic requirements of developed
nations had been met and exploration of safer options to
standard primaquine therapy has not been a research prior-
ity. An experimental drug in phase III trials in 2011 and
intended to replace primaquine, tafenoquine (GlaxoSmithK-
line, UK), presents many of the same limitations with re-
spect to safe use in endemic zones, i.e., hemolytic toxicity
among G6PDd patients. The utility of that drug in most
malaria patients may hinge upon the availability of safe
dosing or G6PDd diagnostics suited for practical use at the
point-of-care typical of endemic zones.
Northern chemotherapeutics has narrowly focused on the
acute attack of falciparum malaria to the exclusion of other
avenues of chemotherapeutics development vital to control-
ling and eliminating the endemic malarias. This neglect
resulted in a single therapeutic option for most other
malarias—primaquine, a 60-year old drug that cannot be
safely applied in endemic zones. Addressing this very broad
problem requires deeper appreciation of the nature of the
entrenched endemic malarias and the need for therapies
aimed at them rather than solely against that which diagno-
sis affirms.
Non-Endemic vs. Endemic Chemotherapeutic Practice
Among residents of the developed world, travelers represent
the primary population affected by malaria. Although out-
breaks of locally acquired malaria sporadically occur, espe-
cially in the United States, the vast majority of patients with
malaria in North America, Europe, and Japan are travelers
who acquire their infections abroad. In the USA in 2009, for
example, 1,478 of 1,484 (99.6%) confirmed malaria cases
were classified as imported; and the remaining 6 patients
were attributed to transfusion, transplant, or possible con-
genital transmission [17•]. Typically more than 98% of
malaria diagnosed in travelers is limited to a single species
[17•, 18–20]. A species-specific diagnosis is often rendered
using molecular diagnostics or reference laboratory micros-
copy, and that diagnosis guides appropriate therapy.
In this setting, malaria is an isolated and relatively rare
clinical problem rather than a broad public health concern.
As such its management is in the hands of providers who
may have little experience with the disease but who typical-
ly have access to state-of-the-art clinical and laboratory
capacities. The treatment of malaria in travelers thus empha-
sizes species-specific therapies in individual patients, guid-
ed by appropriate laboratory evidence and screening against
possible contraindications among therapeutic options, lead-
ing to a very high probability of complete recovery. The
case fatality rate for malaria in the USA in 2009, for exam-
ple, was 0.3% [17•].
In contrast, chemotherapeutic tools, policy and practices
in endemic zones aim at whole populations at risk rather
than isolated patients. The provider of treatment is very
often the patient himself or a neighbor with specialized
and limited training [21, 22•]. Management of malaria by
physicians or nurses in a clinic or hospital often represents a
last resort following the failure of more convenient and less
costly approaches, even in relatively large cities [23]. In
most endemic zones treatment of malaria often comes with-
out a laboratory or rapid diagnostic confirmation of malaria
[21–27], much less screening for contraindications for any
given therapy.
As the example of primaquine starkly illustrates,
therapies suited to healthcare in the developed world
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may prove inadequate to healthcare delivery in the
developing world. The developing world requires che-
motherapeutics that may be safely and effectively ad-
ministered without clinical supervision and risk of
dangerous complications. Further, treatment of malaria
very often occurs without a species diagnosis. Develop-
ment of therapies suited to safe and effective use in advanced
healthcare systems may contribute little to mitigating malaria
as a global problem overwhelmingly borne by the most eco-
nomically disadvantaged people. Chemotherapeutic options
for them must be safe and practical with little clinical and
laboratory capacities.
Non-Endemic vs. Endemic Risks
Other important factors distinguish malaria as a narrow
clinical versus broad public health problem. Endemic ma-
laria encompasses populations hosting all of the malarias,
whether patent, sub-patent, or dormant/latent (Table 1). The
febrile patient with patent parasitemia seeking treatment
likely represents a relatively rare occurrence offering an
opportunity for diagnosis and specific therapy. Most of the
malarias in endemic communities occurring below diagnos-
tic thresholds or capacity (Table 1) supports that likelihood.
Evidence also demonstrates that even a febrile patient suc-
cessfully diagnosed and treated for one species and stage of
parasite, very often carries others. These may be dormant
hypnozoites (for P. vivax and P. ovale) or low-grade and
asymptomatic asexual and sexual parasitemia (all species).
Chemotherapeutic attack on only the species confirmed by
diagnosis likely incurs substantial clinical and public health
risks. This may be most plainly illustrated by the failure to
attack hypnozoites with primaquine even with a diagnosis of
P. vivax, as commonly occurs in endemic zones.
Hypnozoite Reservoir
The experience of the U.S. Army Americal Division at the
battle for Guadalcanal in the Solomon Islands during 1942–
1943 illustrates the vitally important public health conse-
quences of an unchallenged hypnozoite reservoir of infec-
tion (Fig. 1). During January through March 1943 these
soldiers fought on that highly malarious island and were
provided atabrine (also called mepacrine or quinacrine) for
suppressive (blood schizonticidal) chemoprophylaxis. They
nonetheless suffered malaria attack rates of 1.7/person-year.
Prior to their evacuation from Guadalcanal for rest and
recuperation in non-malarious Fiji—anopheline mosquitoes
do not occur east of the Braxton line in the South Pacific—
the soldiers received therapeutic doses of atabrine en masse.
The malaria attack rates on Fiji in this army division,
peaking at 3.7/person-year in August 1943, was all P. vivax
and, given the absence of anopheline mosquitoes, almost
certainly derived from latent hypnozoites [28]. These attack
rates provide a glimpse at possibly heavy public health con-
sequences attending failure to consider and treat silent
malarias like latent P. vivax.
Modern studies affirm such concerns. Douglas et al.
[29••] conducted an exhaustive review of 10,549 study
subjects with naturally acquired (in Thailand and neighbor-
ing nations) acute P. falciparum malaria treated with stan-
dard or experimental therapies for that attack. After 63 days
of observation with little risk of reinfection, 51% of subjects
(receiving rapidly excreted blood schizonticidal therapies
that would not interfere with relapses) had experienced an
attack of P. vivax malaria. That brief period of follow-up
may have missed many subsequent attacks (see Figure) and
the 51% rate may thus be considered a highly conservative
estimate of the prevalence of latent P. vivax among patients
with acute falciparum malaria in the Mekong region. Many
prior studies from that region reported essentially similar
findings [30–32], [33•]. The report of Douglas et al. [29••]
effectively removes doubt regarding a very high prevalence
of one of the silent malarias (the evidence speaks only to
hypnozoites of P. vivax) despite a setting that is considered
relatively low transmission intensity. Hypnozoites in most
endemic zones evidently pose a serious threat to public
health. And yet the only therapy against this malaria, pri-
maquine, cannot be applied due to risk of harm to G6PDd
patients and the inability to effectively and safely exclude
them from treatment.
Mixed Infections
Recent studies also point to blood stage infections in en-
demic zones as often being a mix of species. The diagnosis
Fig. 1 Graph illustrates malaria attack rates among the U.S. Army
Americal Division at Guadalcanal and malaria transmission-free Fiji
during 1943 (adapted from [28]). The attacks of Fiji represent the
burden of disease imposed by untreated relapse of vivax malaria
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of mixed species infection by microscopy is notoriously
difficult and insensitive: the parasitemia tends to be domi-
nated by one species and microscopists often fail to spot the
minority species. Molecular diagnostics usually detect
several-fold higher proportions of mixed infections relative
to standard microscopy. Nested PCR techniques applied to
blood samples from Thailand, for example, found 23% to
24% mixed infections near the Myanmar border, and 3% to
5% in eastern and southern areas of that nation [34]. PCR-
based work in nearby Cambodia showed mixed infection
rates of 23% around Rattanakiri in the northeast [35•].
Mixed infection rates among positives were 6.5% among
samples from Afghanistan, and 22% and 24% among sam-
ples from Iran and Pakistan [36]. A large sample of 2527
residents of hyper- to holo-endemic Papua New Guinea
was analyzed using a multiplex molecular methodology
(ligase detection reaction—fluorescent microsphere as-
say): among the 1844 (73%) positive for any species of
malaria, 61% were positive for a single species of parasite.
Among the others, 30%, 8%, and 1%were positive for 2, 3, or
4 species, respectively [37••]. Mixed species infection of
blood thus typically occurs in about 25% of patients with
malaria in the Asia-Pacific region, and ranges between about
5% and 40%. And yet treatment aims only at that which
diagnosis affirms.
Asymptomatic Parasitemia
The asymptomatic carrier state of blood infection represents
another important risk in endemic zones. Despite the long-
held conviction that effective immunity to febrile illness by
the plasmodia requires chronic and heavy exposure to in-
fection [38, 39], recent evidence casts doubt. In 2008 a mass
blood survey of 9491 residents of Temotu Province, Solo-
mon Islands, for malaria by microscopy experts revealed
only 256 positive patients (2.7%) and only 18% of these
were febrile [40••]. Plasmodium vivax dominated at 82% of
infections, and most of these (66%) were below 100 para-
sites per microliter (40% of P. falciparum were below that
threshold). Examination by PCR diagnostics showed a prev-
alence of 9%, suggesting that <30% of active blood infec-
tions were detected by expert microscopy, and that the rate
of fever with blood infection may have been closer to just
5% despite very low transmission intensity. Essentially sim-
ilar findings have been reported from Amazonia [41, 42•],
Africa [43], the Middle East [44], and Southeast Asia [45,
46]. Most people with malaria in endemic zones will not be
suffering illness and will harbor blood stage parasites below
the detection thresholds of even expert microscopy, and very
far below the widely available rapid diagnostic (RDT) kits
(considered reliable only with >200 parasites/μL [47]). The
reality of an apparently large reservoir of blood infection
beyond diagnostic reach impels consideration of mass drug
administration in the context of elimination strategies [48].
Malaria of Travelers Versus Residents
The silent malarias represent the plasmodia provoking no
symptoms over an extended period and occurring beyond
the reach of available diagnostics. That silence may be a
consequence of biology (hypnozoites & gametocytes do not
cause illness at any density), technology inadequate to di-
agnostic confirmation at a given density, lack of access to a
diagnosis of any sensitivity, or a semi-immune host oblivi-
ous to carrying the infection. Except for the threat of relapse
in travelers, these silent malarias do not register as a chemo-
therapeutics problem in non-endemic settings. As contem-
porary experimental challenge studies demonstrate, non-
immune travelers become acutely ill at very low parasite
densities compared to the chronically exposed [49, 50].
Passive detection and diagnosis of malaria in non-endemic
zones probably captures nearly all infections, but very few
in endemic zones.
Acknowledging endemic malaria as distinct from the strict-
ly clinical problem of non-endemic malaria begins to address
the extremely poor fit of current antimalarial chemotherapeu-
tics development and practice to malaria as it occurs in the
endemic world. The points defined in Table 3 highlight key
distinctions between these two worlds of malaria.
Taken together these distinctions effectively define two
separate malaria problems: non-endemic versus endemic, or
the malaria of travelers versus residents. The importance of
this distinction was made as early as 1902 by Sir Ronald Ross
and is periodically re-emphasized [51]. Nonetheless, the blur-
ring of these two problems in a chemotherapeutics sense
continues to sharply inhibit development of strategies and
tools suitable for practical application in the endemic world.
Endemic Chemotherapeutics Strategy
Greater awareness of the nature of endemic malaria would
likely permit development of more effective strategies for
attacking the silent malarias that dominate those zones. The
long obsession with the acute attack of falciparum malaria,
although obviously a very important problem in any setting,
attended the frank neglect of other important avenues of
chemotherapeutics research and development. The sole
availability of primaquine against hypnozoites and gameto-
cytes, a drug that cannot today be safely used in endemic
zones despite six decades of availability, affirms this neglect
[15•]. Drug discovery should include new tools aimed spe-
cifically at those malarias [52]. In the meantime
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chemotherapeutics and control strategists should consider op-
timizing use of available drugs for endemic settings.
The reality of treatment without diagnosis in endemic
zones, whether by unavailability or inadequate sensitivity,
should be accepted. Abandoning diagnosis-driven species-
specific therapy as the keystone of malaria chemotherapeu-
tics allows development of treatments intended to provide
good efficacy against all species and stages. Primaquine as
the only available hypnozoitocide and gametocytocide
brings focus to the immediate problem: safety in G6PDd
patients. Administering primaquine to all malaria patients,
regardless of G6PDd status or diagnostic outcome or avail-
ability, may not appear impractical or unreasonable if sev-
eral avenues of evidence, long overdue, become developed.
That development may be rationally focused on key dis-
creet questions. Applying hypnozoitocidal primaquine therapy
would almost certainly provide incidental gametocytocidal
coverage. This brings sharp focus to the essential research
question: what hypnozoitocidal regimen of primaquine may
be safely and effectively administered to patients with any
malaria regardless of G6PDd status? TheUSArmy developers
of primaquine addressed this question to vivax malaria in the
1950s and derived an answer: a 45 mg weekly dose of prima-
quine for 8 weeks offered good safety and efficacy against
relapse by P. vivax. Their answer, however, was not universal-
ly applicable because they evaluated only healthy volunteers
having the relatively mild African A- variant of G6PDd, and
very few of them [15•]. That regimen nonetheless provides a
useful starting point for developing a more complete answer to
the essential question. Recent work in Pakistan with the
8-week regimen of primaquine demonstrated good safety
and efficacy, but only a single G6PDd subject was enrolled
[53••]. Is the single weekly 45 mg adult dose safe among
G6PDd variants in a particular area of control operations?
An affirmative answer to this question would provide a
chemotherapeutic tool of immeasurable value to the malaria
control programs responsible for those operations. But
making that determination site-by-site and variant-by-
variant may be impractical and unnecessary. Instead, a glob-
ally relevant answer may be developed that permits treating
all malarias with a single primary therapy proven safe and
effective even in those with G6PDd of the most sensitive
variants. That is the strategic aim. How to realize it?
Rationale for Elimination Therapy Research
and Development
The term radical cure has historically been applied in a
species-specific sense in malariology. Radical cure implies
killing all infecting stages: all blood stages for the non-
relapsing malarias, and all blood and liver stages for the
relapsing malarias. In a practical sense, radical cure means
administering blood schizontocide with gametocytocide
versus blood schizontocide with hypnozoitocide (with inci-
dental gametocytocidal activity) for the non-relapsing and
relapsing species, respectively (Table 1). Aiming at all spe-
cies and stages with a single course of therapy, on the other
hand, may be termed elimination therapy.
Available Tools
The critical need for drug discovery across all of the
malarias has been explained, but the focus here is upon
research applying drugs available in 2011. Therapies aimed
at all of the malarias would include blood schizontocide(s),
hypnozoitocide(s), and gametocytocide(s). Primaquine (and
perhaps tafenoquine) as the only option for the latter two
compartments simplifies the development algorithm, i.e.,
pair it with an appropriate blood schizontocide(s). This is
what the developers of primaquine did with chloroquine and
primaquine in fielding the only radical cure for vivax ma-
laria. The added requirement of efficacy against falciparum
Table 3 Non-Endemic versus Endemic Malarias
Rare versus routine Large developed countries see many hundreds or a few thousand cases of malaria each year; whereas large
undeveloped nations like India or Indonesia likely experience at least several million cases each.
Resource rich versus
resource poor
Almost all malaria cases in the developed world will be managed by physicians, nurses, and laboratorians supported
by state-of-the-art clinical and laboratory facilities; whereas most cases in the developing world will likely be self-
treated or treated by a neighbor with specific training.
Single versus multiple Malaria in travelers will often carry a single confirmed species; whereas residents of endemic zones will be much
more likely to carry an accumulation of silent species and stages beyond diagnostic reach for technical or practical
reasons.
Symptomatic versus
asymptomatic
Most patients in the developed world will experience clinical malaria even with very low parasitemia; whereas most
residents of endemic zones will carry asymptomatic infections in their bloodstream and liver.
Robust versus vulnerable Travel abroad typically precludes the most vulnerable, and travelers thus represent the most robust in both a financial
and health sense; whereas people residing in endemic zones often represent the most vulnerable in both a financial
and health sense.
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malaria should be a relatively simple problem given the
mostly shared susceptibilities to blood schizonticides by
the asexual blood forms (Table 2).
The relatively wide range of therapeutic options for treat-
ment of the asexual blood stages of all species offers
flexibility in optimizing the obligatory hypnozoitocidal pri-
maquine (or tafenoquine) partner for efficacy in elimination
therapy. Maximizing that efficacy also directly addresses the
primary practical concern: increasing safety among many
G6PDd variants. This helps define the evidence needed to
guide decisions on primaquine dosing. That work must
emphasize defining primaquine sensitivity phenotypes
among G6PDd variants, thereby informing strategy for min-
imizing effective hypnozoitocidal/gametocytocidal prima-
quine doses within range of safe tolerability. Figure 2
visualizes this concept. If a synergistic co-drug (s1) dimin-
ishes the minimally effective dose of primaquine to a level
below the hemolytic sensitivity of the most sensitive G6PDd
variant (v4), a dosing window for universally safe treatment
strategy may emerge.
Minimizing Harm—Synergies
Although not widely acknowledged or understood today,
therapeutic activity of primaquine against hypnozoites
requires an appropriate companion drug [54]. When admin-
istered following rather than concurrently with quinine, for
example, primaquine failed against relapse [55]. The same
concurrent dose of primaquine proved less effective
when administered with chloroquine rather than quinine
[55], suggesting chemical class-specific synergistic
effects. An exploration of those effects may yield a
partner hypnozoitocidal drug (whether blood schizonti-
cidal or not) yielding less threatening therapeutic doses
of primaquine. Indeed, recent work with tafenoquine
against the Plasmodium cynomolgi model of P. vivax
relapse in rhesus macaques showed a 10-fold reduction
in the minimal effective dose of that drug when admin-
istered with blood schizontocide [56••]. Likewise, the
widely used ACTs show good activity against young but not
mature gametocytes; optimizing ACT-primaquine to gameto-
cytocidal activity may also yield less threatening dosing—a
strategy that may prove vitally important in Africa where
hypnozoitocidal therapies may not be indicated by virtue of
the relative paucity of vivax malaria.
Preventing Harm—G6PDd Screening
The core G6PDd problem with primaquine, and therefore
elimination therapy, may also be addressed by a point-of-
care diagnostic that is robust in endemic settings and across
variants and clinical conditions. The kit must reliably ex-
clude those at risk under almost all circumstances of therapy,
including variable genotypes of G6PDd, states of heterozy-
gosity among females (lyonization of this X-linked trait),
and states of disease caused by malaria and other infections
or nutritional and physiological disorders. This approach,
like that of fielding a universally safe regimen of primaquine
or tafenoquine, requires certain knowledge of hemolytic
sensitivity phenotypes among G6PDd variants. Today
only scanty evidence informs that critical knowledge base.
G6PDd Sensitivity Phenotype as a Core
Chemotherapeutics Research Agenda
Development of elimination therapy requires characterizing
primaquine sensitivity phenotypes among a range of ratio-
nally selected G6PDd variants. Among the many dozens of
known variants, primaquine sensitivity phenotype has been
characterized for only three: African A-, Mahidol, and Med-
iterranean B-. These represent mild, moderate, and severe
phenotypes, respectively. The residual enzyme activity
among these variants happens to inversely correlate with
that sensitivity. The same relationship is often presumed to
exist among the many other variants [57], but this has not
yet been quantitatively demonstrated. At least one case
illustrates the uncertainty in this correlation: an Iranian
G6PDd patient with 19% residual enzyme activity (approx-
imately that typically observed in mildly primaquine sensi-
tive African A- subjects) suffered a deep hemolysis and
required blood transfusion after a single 45 mg dose of
primaquine [58]. Research should be aimed at filling
Fig. 2 The relationship between safety & efficacy with primaquine
among the G6PDd. Hypothetical primaquine dosing (dark 0 high dose;
light 0 low dose) among G6PDd variants of variable sensitivities (v4
most sensitive) and synergistic effects of other drugs administered with
primaquine (s1 most synergistic) against relapse revealing dosing at
which universally safe and efficacious primaquine therapy may be
possible, i.e., when administered with s1 or s2 effects. Each line
represents the division between hemolytic vs. safe (yellow lines), and
efficacious vs. inefficacious (red lines) for each given variant or co-
drug, respectively
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important gaps in understanding the mechanism(s) underly-
ing primaquine toxicity process and consequence among
G6PDd variants. That ranges from relatively inconsequen-
tial to life threatening and the key determinants remain
unknown.
Two common variants illustrate the profound differ-
ences between them with respect to primaquine sensi-
tivity. Healthy African-American subjects with A-
G6PDd experience a relatively mild and self-limiting
primaquine-induced hemolysis. As susceptible older red
blood cells are replaced, hemolytic sensitivity vanishes.
In one clinical trial African A- G6PDd subjects received
30 mg primaquine daily for over 4 months: hematocrit
levels troughed at about 30% hemolysis after 10 days
and recovered to normal levels within 2 weeks despite
continuing exposure to that high dose of primaquine
[59]. This self-limiting toxicity contrasts with that in
subjects with Mediterranean B- G6PDd. In those sub-
jects even reticulocytes and younger red blood cells replac-
ing hemolyzed red blood cell populations remained
exquisitely primaquine-sensitive: hemolysis deepened
with each daily dose [60]. The obvious choice of vari-
ant for exploring universally tolerable and safe regimens
of primaquine would be a variant like Mediterranean B-.
Dosing regimens tolerated by these patients would like-
ly also prove tolerable among patients with most other
variants (Fig. 2).
Studies of complete G6PD gene sequences among pop-
ulations of G6PDd variants may reveal even deeper com-
plexity in the primaquine sensitivity problem. Common
variants have been conventionally identified by enzyme
biochemistry phenotypes (mobility, stability, substrate ki-
netics) linked to single mutations confirmed by restric-
tion fragment length polymorphisms or sequencing only
tiny fragments of the G6PD gene. This very large gene,
however, may contain a host of other single nucleotide
polymorphisms (SNPs) relevant to primaquine sensitivi-
ty phenotype [61]. Complete G6PD gene analyses of
variants representing distinct primaquine sensitivity pheno-
types may radically improve understanding of essential
aspects of the phenomenon.
The essential research and development question,
“What hypnozoitocidal regimen of primaquine may be
safely administered to patients with any malaria regard-
less of G6PDd status?” may be focused upon variants
of greatest sensitivity to primaquine (per Fig. 2). Avail-
able data on primaquine sensitivity in the most-sensitive
(thus far known) Mediterranean B- does not preclude
the possibility of safe and effective dosing. It is known
only that sustained daily dosing with the relatively high
30 mg dose constitutes a potentially lethal threat to such
patients [60]. A unique characteristic of the hypnozoitocidal
activity of primaquine (called the total dose effect)
offers the possibility of safe and efficacious options,
i.e., lower doses over longer periods. A single total dose
of primaquine, whether administered at once or weekly
over many weeks, provided equally efficacious activity
against relapse [62, 63]. This unique characteristic was
exploited by the developers of primaquine in identifying
the 45 mg weekly primaquine dose for 8 weeks. The
safety of this regimen in Mediterranean B- or similarly
very sensitive variants has not been evaluated. Finally
doing so may be the first step in the overdue exploration of
elimination therapies.
Establishing the safety of a weekly 45 mg dose for
8 weeks in the most vulnerable G6PDd patients would
provide national malaria control programs with the ev-
idence required to assertively and confidently apply
primaquine as routine therapy without G6PDd screen-
ing. On the other hand, if primaquine at this dose
indeed threatens such patients, especially those already
acutely ill with malaria, then the necessity of optimized
lower doses of primaquine (Fig. 2), or of point-of-care
G6PDd screening kit would be appreciated as necessary
in developing and fielding elimination therapies. Pursuit
of either avenue requires much greater understanding of
primaquine sensitivity genotypes and phenotypes among
G6PDd variants.
Critical Questions
Working to develop elimination therapies in the short
term requires addressing critical questions regarding the
hemolytic toxicity of primaquine and other 8-aminoquinolines
among the G6PDd. Although malariologists often cite
parasite resistance to drugs as a key determinant of
inadequate control of endemic malaria, it seems likely
that the long-standing strategy of partial and fragmented
chemotherapeutic attack may also explain that problem.
The search for solutions to what is perhaps the essence
of persistent endemic malaria should focus upon prima-
quine and tafenoquine safety across important G6PDd
variants, and their efficacies across chemotherapeutic
compartments.
1. Does G6PDd residual enzyme activity correlate with
primaquine sensitivity phenotype among the G6PDd?
2. What G6PDd genotypes are linked to primaquine sen-
sitivity phenotype?
3. What are the most vulnerable G6PDd genotypes and
their frequencies and geographic distributions?
4. What is the threshold of exposure to primaquine among
most sensitive G6PDd variants that may be considered
not threatening to patient safety?
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5. Can the hypnozoitocidal and gametocytocidal doses
of primaquine and other 8-aminoquinolines be sub-
stantially reduced by application with other drugs that
maximally synergize that activity, whether blood schizo-
nticidal or not?
6. Can optimized hypnozoitocidal and gametocytocidal
therapies be translated into dosing that is safe and ef-
fective in the most vulnerable G6PDd variants?
7. Can a point-of-care diagnostic for G6PDd safely ex-
clude patients at risk of harm caused by any regimen
of primaquine, and do so at very low cost without the
need for a cold chain or laboratory capacities?
Conclusions
The extraordinary efficacy of primaquine and other 8-
aminoquinolines in killing across species and stages of
plasmodia has not been capitalized as a result of the hemo-
lytic toxicity of this class of compounds among G6PDd
patients. G6PDd and the failure to develop practical
solutions to this problem may explain the absence of
elimination therapy in the malaria control toolbox. That
failure stems from another: little appreciation of the
important distinctions between non-endemic and endem-
ic malarias as regards chemotherapeutics strategies and
practice. Clinical investigators in endemic zones have
raised the issue of elimination therapy for all malarias
[64], but the possibility of safe and effective regimens
of primaquine combined with blood schizonticides and
aimed at elimination therapy remains largely unex-
plored. Drug development paradigms today remain high-
ly segregated by type of malaria, and largely focused
upon blood schizonticides for acute falciparum malaria.
Development of drug combinations against all malarias may
provide a means of fielding therapies appropriate and effective
in endemic settings. Current strategy and practice, well suited
to malaria as it occurs in developed nations, leaves most of the
malarias in endemic zones unchallenged.
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